Arginine
|
|
| Names |
| Other names
2-Amino-5-guanidinopentanoic acid
|
| Identifiers |
|
CAS Number
|
- 7200-25-1 N
- 157-06-2 R N
- 74-79-3 S N
|
|
3D model (JSmol)
|
- Interactive image
- Interactive image
|
| 3DMet |
B01331 |
|
Beilstein Reference
|
1725411, 1725412 R, 1725413 S |
| ChEBI |
|
| ChemSpider |
|
| DrugBank |
|
| ECHA InfoCard |
100.000.738 |
| EC Number |
230-571-3 |
|
Gmelin Reference
|
364938 R |
|
IUPHAR/BPS
|
|
| KEGG |
|
| MeSH |
Arginine |
|
|
|
| RTECS number |
CF1934200 S |
| UNII |
|
InChI
-
InChI=1S/C6H14N4O2/c7-4(5(11)12)2-1-3-10-6(8)9/h4H,1-3,7H2,(H,11,12)(H4,8,9,10) Y
Key: ODKSFYDXXFIFQN-UHFFFAOYSA-N Y
|
SMILES
-
NC(CCCNC(N)=N)C(O)=O
-
NC(CCC[nH]:c(:[nH]):[nH2])c(:[o]):[oH]
|
| Properties |
|
Chemical formula
|
C6H14N4O2 |
| Molar mass |
174.20 g·mol−1 |
| Appearance |
White crystals |
| Odor |
Odourless |
| Melting point |
260 °C; 500 °F; 533 K |
| Boiling point |
368 °C (694 °F; 641 K) |
|
Solubility in water
|
14.87 g/100 mL (20 °C) |
| Solubility |
slightly soluble in ethanol
insoluble in ethyl ether |
| log P |
−1.652 |
| Acidity (pKa) |
12.488 |
| Basicity (pKb) |
1.509 |
| Thermochemistry |
|
Specific
heat capacity (C)
|
232.8 J K−1 mol−1 (at 23.7 °C) |
|
Std molar
entropy (So298)
|
250.6 J K−1 mol−1 |
|
Std enthalpy of
formation (ΔfHo298)
|
−624.9–−622.3 kJ mol−1 |
|
Std enthalpy of
combustion (ΔcHo298)
|
−3.7396–−3.7370 MJ mol−1 |
| Pharmacology |
|
ATC code
|
B05XB01 (WHO) S |
| Hazards |
| Safety data sheet |
See: data page
sigma-aldrich |
| GHS pictograms |
|
| GHS signal word |
WARNING |
|
GHS hazard statements
|
H319 |
|
GHS precautionary statements
|
P305+351+338 |
| Lethal dose or concentration (LD, LC): |
|
LD50 (median dose)
|
5110 mg/kg (rat, oral) |
| Related compounds |
|
Related alkanoic acids
|
- N-Methyl-D-aspartic acid
- beta-Methylamino-L-alanine
- Guanidinopropionic acid
- Theanine
- Pantothenic acid
|
|
Related compounds
|
|
| Supplementary data page |
|
Structure and
properties
|
Refractive index (n),
Dielectric constant (εr), etc. |
|
Thermodynamic
data
|
Phase behaviour
solid–liquid–gas |
|
Spectral data
|
UV, IR, NMR, MS |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
| N verify (what is YN ?) |
| Infobox references |
|
|
Arginine (abbreviated as Arg or R) is an α-amino acid that is used in the biosynthesis of proteins. It is encoded by the codons CGU, CGC, CGA, CGG, AGA, and AGG.[1] It contains an α-amino group, an α-carboxylic acid group, and a side chain consisting of a 3-carbon aliphatic straight chain ending in a guanidino group. At physiological pH, the carboxylic acid is deprotonated (−COO−), the amino group is protonated (−NH3+), and the guanidino group is also protonated to give the guanidinium form (-C-(NH2)2+), making arginine a charged, aliphatic amino acid.[2] It is the precursor for the biosynthesis of nitric oxide.
In humans, arginine is classified as a semiessential or conditionally essential amino acid, depending on the developmental stage and health status of the individual.[3] Preterm infants are unable to synthesize or create arginine internally, making the amino acid nutritionally essential for them.[4] Most healthy people do not need to supplement with arginine because it is a component of all protein-containing foods[5] and can be synthesized in the body from glutamine via citrulline.[6]
Contents
- 1 History
- 2 Sources
- 2.1 Dietary sources
- 2.2 Biosynthesis
- 3 Function
- 3.1 Proteins
- 3.2 Precursor
- 3.3 Safety
- 4 Structure
- 5 Research
- 5.1 Growth hormone
- 5.2 High blood pressure
- 6 See also
- 7 References
- 8 External links
History
Arginine was first isolated from lupin and pumpkin seedlings by the German chemist Ernst Schulze and his assistant[7] Ernst Steiger. They confirmed and published the structure in 1886.[8]
Sources
Dietary sources
Arginine is a conditionally essential amino acid in humans and rodents,[9] as it may be required depending on the health status or life cycle of the individual. For example, while healthy adults can supply their own requirement for arginine, immature and rapidly growing individuals require arginine in their diet,[10] and it is also essential under physiological stress, for example during recovery from burns, injury and sepsis,[10] or when the small intestine and kidneys, which are the major sites of arginine biosynthesis have been damaged.[9] It is, however, an essential amino acid for birds, as they do not have a urea cycle.[11] For some carnivores, for example cats, dogs[12] and ferrets, arginine is essential,[9] because after a meal, their highly efficient protein catabolism produces large quantities of ammonia which needs to be processed through the urea cycle, and if there is not enough arginine present, the resulting ammonia toxicity can be lethal.[13] This is not a problem in practice, because meat contains sufficient arginine to avoid this situation.[13]
Animal sources of arginine include meat, dairy products and eggs,[14][15] and plant sources include seeds of all types, for example grains, beans, and nuts.[15]
Biosynthesis
Arginine is synthesized from citrulline in arginine and proline metabolism by the sequential action of the cytosolic enzymes argininosuccinate synthetase (ASS) and argininosuccinate lyase (ASL). This is an energetically costly process, because for each molecule of argininosuccinate that is synthesized, one molecule of adenosine triphosphate (ATP) is hydrolyzed to adenosine monophosphate (AMP), consuming two ATP equivalents.
Citrulline can be derived from multiple sources:
- from arginine itself via nitric oxide synthase (NOS), as a byproduct of the production of nitric oxide for signaling purposes
- from ornithine through the breakdown of proline or glutamine/glutamate
- from asymmetric dimethylarginine (ADMA) via DDAH
The pathways linking arginine, glutamine, and proline are bidirectional. Thus, the net utilization or production of these amino acids is highly dependent on cell type and developmental stage.
On a whole-body basis, synthesis of arginine occurs principally via the intestinal–renal axis: the epithelial cells of the small intestine produce citrulline, primarily from glutamine and glutamate, which is carried in the bloodstream to the proximal tubule cells of the kidney, which extract citrulline from the circulation and convert it to arginine, which is returned to the circulation. This means that impaired small bowel or renal function can reduce arginine synthesis, increasing the dietary requirement.
Synthesis of arginine from citrulline also occurs at a low level in many other cells, and cellular capacity for arginine synthesis can be markedly increased under circumstances that increase the production of inducible NOS (iNOS). This allows citrulline, a byproduct of the NOS-catalyzed production of nitric oxide, to be recycled to arginine in a pathway known as the citrulline-NO or arginine-citrulline pathway. This is demonstrated by the fact that, in many cell types, NO synthesis can be supported to some extent by citrulline, and not just by by arginine. This recycling is not quantitative, however, because citrulline accumulates in NO-producing cells along with nitrate and nitrite, the stable end-products of NO breakdown.[16]
Function
Arginine plays an important role in cell division, wound healing, removing ammonia from the body, immune function,[17] and the release of hormones.[3][18][19] It is a precursor for the synthesis of nitric oxide (NO),[20] making it important in the regulation of blood pressure.[21][22][23]
Proteins
Arginine's side chain is amphipathic, because at physiological pH it contains a positively charged guanidinium group, which is highly polar, at the end of a hydrophobic aliphatic hydrocarbon chain. Because globular proteins have hydrophobic interiors and hydrophilic surfaces,[24] arginine is typically found on the outside of the protein, where the hydrophilic head group can interact with the polar environment, for example taking part in hydrogen bonding and salt bridges.[25] For this reason, it is frequently found at the interface between two proteins.[26] The aliphatic part of the side chain sometimes remains below the surface of the protein.[25]
Arginine residues in proteins can be deiminated by PAD enzymes to form citrulline, in a post-translational modification process called citrullination.This is important in fetal development, is part of the normal immune process, as well as the control of gene expression, but is also significant in autoimmune diseases.[27]:275 Another post-translational modification of arginine involves methylation by protein methyltransferases.[27]:176
Precursor
Arginine is the immediate precursor of nitric oxide (NO), an important signaling molecule which can act as a second messenger as well as an intercellular messenger which regulates vasodilation, and also has functions in the immune system's reaction to infection.
Arginine is also a precursor for urea, ornithine, and agmatine; is necessary for the synthesis of creatine; and can also be used for the synthesis of polyamines (mainly through ornithine and to a lesser degree through agmatine), citrulline, and glutamate. The presence of asymmetric dimethylarginine (ADMA), a close relative, inhibits the nitric oxide reaction; therefore, ADMA is considered a marker for vascular disease, just as L-arginine is considered a sign of a healthy endothelium.
Safety
L-arginine is generally recognized as safe (GRAS-status) at intakes of up to 20 grams per day.[28]
Structure
Delocalization of charge in guanidinium group of L-Arginine
The amino acid side-chain of arginine consists of a 3-carbon aliphatic straight chain, the distal end of which is capped by a guanidinium group, which has a pKa of 12.48, and is therefore always protonated and positively charged at physiological pH. Because of the conjugation between the double bond and the nitrogen lone pairs, the positive charge is delocalized, enabling the formation of multiple hydrogen bonds.
Research
Growth hormone
Intravenously-administered arginine is used in growth hormone stimulation tests[29] because it stimulates the secretion of growth hormone.[30] A review of clinical trials concluded that oral arginine increases growth hormone.[31] However, a more recent trial reported that although oral arginine increased plasma levels of L-arginine it did not cause an increase in growth hormone.[32]
High blood pressure
A meta-analysis showed that L-arginine reduces blood pressure with pooled estimates of 5.4 mmHg for systolic blood pressure and 2.7 mmHg for diastolic blood pressure.[23]
Supplementation with L-arginine reduces diastolic blood pressure and lengthens pregnancy for women with gestational hypertension, including women with high blood pressure as part of pre-eclampsia. It did not lower systolic blood pressure or improve weight at birth.[33]
See also
- Arginine glutamate
- AAKG
- Canavanine and canaline are toxic analogs of arginine and ornithine.
References
- ^ IUPAC-IUBMB Joint Commission on Biochemical Nomenclature. "Nomenclature and Symbolism for Amino Acids and Peptides". Recommendations on Organic & Biochemical Nomenclature, Symbols & Terminology etc. Archived from the original on 29 May 2007. Retrieved 2007-05-17.
- ^ Glasel, Jay A.; Deutscher, Murray P. (1995-11-20). Introduction to Biophysical Methods for Protein and Nucleic Acid Research. Academic Press. p. 456. ISBN 9780080534985.
- ^ a b Tapiero H, Mathé G, Couvreur P, Tew KD (November 2002). "L-Arginine". (review). Biomedicine & Pharmacotherapy. 56 (9): 439–445. doi:10.1016/s0753-3322(02)00284-6.
- ^ Wu G, Jaeger LA, Bazer FW, Rhoads JM (Aug 2004). "Arginine deficiency in preterm infants: biochemical mechanisms and nutritional implications". (review). The Journal of Nutritional Biochemistry. 15 (8): 442–51. doi:10.1016/j.jnutbio.2003.11.010. PMID 15302078.
- ^ "Drugs and Supplements Arginine". Retrieved 15 January 2015.
- ^ Skipper, Annalynn (1998). Dietitian's Handbook of Enteral and Parenteral Nutrition. Jones & Bartlett Learning. p. 76. ISBN 9780834209206.
- ^ Apel, Frank (July 2015). "Biographie von Ernst Schulze" (PDF). Retrieved 2017-11-06.
- ^ Schulze, Ernst; Steiger, Ernst (1887). "Ueber das Arginin". Zeitschrift für physiologische Chemie. 11 (1-2): 43–65.
- ^ a b c Ignarro, Louis J. (2000-09-13). Nitric Oxide: Biology and Pathobiology. Academic Press. p. 189. ISBN 9780080525037.
- ^ a b Borlase, Bradley C. (1994). Enteral Nutrition. Jones & Bartlett Learning. p. 48. ISBN 9780412984716.
- ^ Freedland, Richard Allan; Briggs, Stephanie (2012-12-06). A Biochemical Approach to Nutrition. Springer Science & Business Media. p. 45. ISBN 9789400957329.
- ^ Nutrient Requirements of Dogs. National Academies Press. 1985. p. 65. ISBN 9780309034968.
- ^ a b Wortinger, Ann; Burns, Kara (2015-06-11). Nutrition and Disease Management for Veterinary Technicians and Nurses. John Wiley & Sons. p. 232. ISBN 9781118811085.
- ^ Spano, Marie A.; Kruskall, Laura J.; Thomas, D. Travis (2017-08-30). Nutrition for Sport, Exercise, and Health. Human Kinetics. p. 240. ISBN 9781450414876.
- ^ a b Watson, Ronald Ross; Zibadi, Sherma (2012-11-28). Bioactive Dietary Factors and Plant Extracts in Dermatology. Springer Science & Business Media. p. 75. ISBN 9781627031677.
- ^ Morris SM (Oct 2004). "Enzymes of arginine metabolism". (review). The Journal of Nutrition. 134 (10 Suppl): 2743S–2747S; discussion 2765S–2767S. PMID 15465778.
- ^ Mauro, Claudio; Frezza, Christian (2015-07-13). The Metabolic Challenges of Immune Cells in Health and Disease. Frontiers Media SA. p. 17. ISBN 9782889196227.
- ^ Stechmiller JK, Childress B, Cowan L (Feb 2005). "Arginine supplementation and wound healing". (review). Nutrition in Clinical Practice. 20 (1): 52–61. doi:10.1177/011542650502000152. PMID 16207646.
- ^ Witte MB, Barbul A (2003). "Arginine physiology and its implication for wound healing". (review). Wound Repair and Regeneration. 11 (6): 419–23. doi:10.1046/j.1524-475X.2003.11605.x. PMID 14617280.
- ^ Andrew PJ, Mayer B (Aug 1999). "Enzymatic function of nitric oxide synthases". (review). Cardiovascular Research. 43 (3): 521–31. doi:10.1016/S0008-6363(99)00115-7. PMID 10690324.
- ^ Gokce N (Oct 2004). "L-arginine and hypertension". (review). The Journal of Nutrition. 134 (10 Suppl): 2807S–2811S; discussion 2818S–2819S. PMID 15465790.
- ^ Rajapakse NW, De Miguel C, Das S, Mattson DL (Dec 2008). "Exogenous L-arginine ameliorates angiotensin II-induced hypertension and renal damage in rats". (primary). Hypertension. 52 (6): 1084–90. doi:10.1161/HYPERTENSIONAHA.108.114298. PMC 2680209 . PMID 18981330.
- ^ a b Dong JY, Qin LQ, Zhang Z, Zhao Y, Wang J, Arigoni F, Zhang W (Dec 2011). "Effect of oral L-arginine supplementation on blood pressure: a meta-analysis of randomized, double-blind, placebo-controlled trials". review. American Heart Journal. 162 (6): 959–965. doi:10.1016/j.ahj.2011.09.012. PMID 22137067.
- ^ Mathews, Christopher K.,; Van Holde, Kensal Edward; Ahern, Kevin G. (2000). Biochemistry (3rd ed.). San Francisco, Calif.: Benjamin Cummings. p. 180. ISBN 0805330666. OCLC 42290721.
- ^ a b Barnes, Michael R. (2007-04-16). Bioinformatics for Geneticists: A Bioinformatics Primer for the Analysis of Genetic Data. John Wiley & Sons. p. 326. ISBN 9780470026199.
- ^ Kleanthous, Colin (2000). Protein-protein Recognition. Oxford University Press. p. 13. ISBN 9780199637607.
- ^ a b Griffiths, John R.; Unwin, Richard D. (2016-10-12). Analysis of Protein Post-Translational Modifications by Mass Spectrometry. John Wiley & Sons. ISBN 9781119250883.
- ^ Shao A, Hathcock JN (2008). "Risk assessment for the amino acids taurine, L-glutamine and L-arginine". Regul Toxicol Pharmacol. 50 (3): 376–399. doi:10.1016/j.yrtph.2008.01.004. PMID 18325648.
- ^ U.S. National Library of Medicine (September 2009 Growth hormone stimulation test
- ^ Alba-Roth J, Müller OA, Schopohl J, von Werder K (Dec 1988). "Arginine stimulates growth hormone secretion by suppressing endogenous somatostatin secretion". The Journal of Clinical Endocrinology and Metabolism. 67 (6): 1186–9. doi:10.1210/jcem-67-6-1186. PMID 2903866.
- ^ Kanaley JA (2008). "Growth hormone, arginine and exercise". Curr Opin Clin Nutr Metab Care. 11 (1): 50–4. doi:10.1097/MCO.0b013e3282f2b0ad. PMID 18090659.
- ^ Forbes SC, Bell GJ (2011). "The acute effects of a low and high dose of oral L-arginine supplementation in young active males at rest". Appl Physiol Nutr Metab. 36 (3): 405–11. doi:10.1139/h11-035. PMID 21574873.
- ^ Gui S, Jia J, Niu X, Bai Y, Zou H, Deng J, Zhou R (Mar 2014). "Arginine supplementation for improving maternal and neonatal outcomes in hypertensive disorder of pregnancy: a systematic review". (review). Journal of the Renin-Angiotensin-Aldosterone System. 15 (1): 88–96. doi:10.1177/1470320313475910. PMID 23435582.
External links
|
Wikimedia Commons has media related to arginine. |
- NIST Chemistry Webbook
- Mayo Clinic discussion of Arginine.
- National Institute of Health discussion of Arginine.
|
The encoded amino acid
|
| General topics |
- Protein
- Peptide
- Genetic code
|
|
| By properties |
| Aliphatic |
- Branched-chain amino acids (Valine
- Isoleucine
- Leucine)
- Methionine
- Alanine
- Proline
- Glycine
|
| Aromatic |
- Phenylalanine
- Tyrosine
- Tryptophan
- Histidine
|
| Polar, uncharged |
- Asparagine
- Glutamine
- Serine
- Threonine
|
| Positive charge (pKa) |
- Lysine (≈10.8)
- Arginine (≈12.5)
- Histidine (≈6.1)
|
| Negative charge (pKa) |
- Aspartic acid (≈3.9)
- Glutamic acid (≈4.1)
- Cysteine (≈8.3)
- Tyrosine (≈10.1)
|
|
| Other classifications |
- Essential amino acid
- Ketogenic amino acid
- Glucogenic amino acid
- Non-proteinogenic amino acid
|
|
Amino acid metabolism metabolic intermediates
|
| K→acetyl-CoA |
| lysine→ |
- Saccharopine
- Allysine
- α-Aminoadipic acid
- α-Ketoadipate
- Glutaryl-CoA
- Glutaconyl-CoA
- Crotonyl-CoA
- β-Hydroxybutyryl-CoA
|
| leucine→ |
- β-Hydroxy β-methylbutyric acid
- β-Hydroxy β-methylbutyryl-CoA
- Isovaleryl-CoA
- α-Ketoisocaproic acid
- β-Ketoisocaproic acid
- β-Ketoisocaproyl-CoA
- β-Leucine
- β-Methylcrotonyl-CoA
- β-Methylglutaconyl-CoA
- β-Hydroxy β-methylglutaryl-CoA
|
| tryptophan→alanine→ |
- N'-Formylkynurenine
- Kynurenine
- Anthranilic acid
- 3-Hydroxykynurenine
- 3-Hydroxyanthranilic acid
- 2-Amino-3-carboxymuconic semialdehyde
- 2-Aminomuconic semialdehyde
- 2-Aminomuconic acid
- Glutaryl-CoA
|
|
| G |
| G→pyruvate→citrate |
| glycine→serine→ |
- glycine→creatine: Glycocyamine
- Phosphocreatine
- Creatinine
|
|
G→glutamate→
α-ketoglutarate |
| histidine→ |
- Urocanic acid
- Imidazol-4-one-5-propionic acid
- Formiminoglutamic acid
- Glutamate-1-semialdehyde
|
| proline→ |
- 1-Pyrroline-5-carboxylic acid
|
| arginine→ |
- Agmatine
- Ornithine
- Citrulline
- Cadaverine
- Putrescine
|
| other |
- cysteine+glutamate→glutathione: γ-Glutamylcysteine
|
|
G→propionyl-CoA→
succinyl-CoA |
| valine→ |
- α-Ketoisovaleric acid
- Isobutyryl-CoA
- Methacrylyl-CoA
- 3-Hydroxyisobutyryl-CoA
- 3-Hydroxyisobutyric acid
- 2-Methyl-3-oxopropanoic acid
|
| isoleucine→ |
- 2,3-Dihydroxy-3-methylpentanoic acid
- 2-Methylbutyryl-CoA
- Tiglyl-CoA
- 2-Methylacetoacetyl-CoA
|
| methionine→ |
- generation of homocysteine: S-Adenosyl methionine
- S-Adenosyl-L-homocysteine
- Homocysteine
- conversion to cysteine: Cystathionine
- alpha-Ketobutyric acid+Cysteine
|
| threonine→ |
|
| propionyl-CoA→ |
|
|
| G→fumarate |
| phenylalanine→tyrosine→ |
- 4-Hydroxyphenylpyruvic acid
- Homogentisic acid
- 4-Maleylacetoacetic acid
|
|
| G→oxaloacetate |
|
|
| Other |
|
|
Nitric oxide signaling modulators
|
| Forms |
- Nitroxyl anion (NO−; oxonitrate(1-), hyponitrite anion)
- Nitric oxide (NO⋅; nitrogen monoxide)
- Nitrosonium (NO+; nitrosyl cation)
|
| Targets |
| sGC |
- Activators: Cinaciguat (BAY 58-2667)
- Riociguat (BAY 63-2521)
|
|
NO donors
(prodrugs) |
- Nitrates: Diethylene glycol dinitrate (DEGDN)
- Erythritol tetranitrate (ETN)
- Ethylene glycol dinitrate (EGDN; nitroglycol)
- Isosorbide mononitrate (ISMN)
- Isosorbide dinitrate (ISDN)
- Itramin tosilate
- Mannitol hexanitrate
- Naproxcinod (nitronaproxen; AZD-3582, HCT-3012)
- NCX-466
- NCX-2216
- NCX-4016
- NCX 4040
- NCX-4215
- Nicorandil
- Nipradilol (K-351)
- Nitrate (NO−
3)
- Nitroatorvastatin (NCX-6560)
- Nitroflurbiprofen (HCT-1026)
- Nitrofluvastatin
- Nitroglycerin (glyceryl trinitrate (GTN))
- Nitropravastatin (NCX-6550)
- Pentaerithrityl tetranitrate (PETN)
- Propatylnitrate
- Propylene glycol dinitrate (PGDN)
- Sodium trioxodinitrate (Angeli's salt)
- Tenitramine
- Trolnitrate
- Nitroso compounds/nitrites: Nitrite (NO−
2); O-Nitroso compounds (alkyl nitrites): Amyl nitrite (isoamyl nitrite, isopentyl nitrite)
- Cyclohexyl nitrite
- Ethyl nitrite
- Hexyl nitrite
- Isobutyl nitrite (2-methylpropyl nitrite)
- Isopropyl nitrite
- Methyl nitrite
- n-Butyl nitrite
- Pentyl nitrite
- tert-Butyl nitrite; S-Nitroso compounds (thionitrites): LA810
- S-Nitrosoalbumin (SNALB)
- S-Nitrosated AR545C
- S-Nitroso-N-acetylcysteine (SNAC)
- S-Nitroso-N-acetylpenicillamine (SNAP)
- S-Nitroso-N-valerylpenicillamine (SNVP)
- S-Nitrosocaptopril (SNO-Cap)
- S-Nitrosocysteine (SNC, CysNO, SNO-Cys)
- S-Nitrosodiclofenac
- S-Nitrosoglutathione (GSNO, SNOG)
- SNO-t-PA
- SNO-vWF; N-Nitroso compounds (e.g., nitrosamines): SIN-1A
- Nitrosyl compounds: Metal nitrosyl complexes: Roussin's black salt
- Roussin's red salt
- Sodium nitroprusside (SNP)
- NONOates (diazeniumdiolates): Diethylamine/NO (DEA/NO)
- Diethylenetriamine/NO (DETA/NO)
- GLO/NO
- JS-K
- Methylamine hexamethylene methylamine/NO (MAHMA/NO)
- PROLI/NO
- Spermine/NO (SPER/NO)
- V-PYRRO/NO
- Heterocyclic compounds: Furoxans: Furoxan
- REC15/2739; Sydnonimines: Feprosidnine
- Linsidomine (SIN-1)
- Molsidomine (SIN-10)
- Sydnonimine
- Unsorted: CXL-1427
- FK-409
- FR144220
- FR146881
- N-Acetyl-N-acetoxy-4-chlorobenzenesulfonamide
|
Enzyme
(inhibitors) |
| NOS |
| nNOS |
- 3-Bromo-7-nitroindazole
- 3-Chloroindazole
- 3-Chloro-5-nitroindazole
- 5-Nitroindazole
- 6-Nitroindazole
- 7-Nitroindazole
- A-84643
- Aminoguanidine (pimagedine)
- ARL-17477
- Indazole
- N5-(1-Iminoethyl)-L-ornithine (L-NIO)
- Nω-Methyl-L-arginine (L-NMA)
- Nω-Propyl-L-arginine (L-NPA)
- Nitroarginine (NNA, NOARG)
- Pentamidine isethionate
- TRIM
|
| iNOS |
- 1-Amino-2-hydroxyguanidine
- 2-Ethylaminoguanidine
- 2-Iminopiperidine
- 1400W
- AEITU
- Aminoguanidine (pimagedine)
- AMT
- AR-C 102222
- BYK-191023
- Canavanine
- Cindunistat (SD-6010)
- EITU
- IPTU
- MITU
- N5-(1-Iminoethyl)-L-ornithine (L-NIO)
- N6-(1-Iminoethyl)-L-lysine (L-NIL)
- Nω-Methyl-L-arginine (L-NMA)
- Ronopterin (VAS-203)
- TRIM
|
| eNOS |
- Aminoguanidine (pimagedine)
- N5-(1-Iminoethyl)-L-ornithine (L-NIO)
- Nω-Methyl-L-arginine (L-NMA)
- Nitroarginine (NNA, NOARG)
|
| Unsorted |
- Asymmetric dimethylarginine (ADMA)
- CKD-712
- Guanidinoethyldisulfide (GED)
- GW-273629
- Indospicine
- KD-7040
- Nitroarginine methyl ester (NAME)
- NCX-456
- NXN-462
- ONO-1714
- VAS-2381
|
|
| Arginase |
- ABH
- Nω-Hydroxy-L-arginine (NOHA)
|
| CAMK |
|
|
| Others |
- Precursors: L-Arginine
- Nω-Hydroxy-L-arginine (NOHA)
- Cofactors: NADPH
- FAD
- FMN
- Heme
- BH4
- CaM
- O2
- Ca2+
- Indirect/downstream NO modulators: ACE inhibitors/AT-II receptor antagonists (e.g., captopril, losartan)
- ETB receptor antagonists (e.g., bosentan)
- L-Type calcium channel blockers (e.g., dihydropyridines: nifedipine)
- Nebivolol (beta blocker)
- PDE5 inhibitors (e.g., sildenafil)
- Statins (e.g., simvastatin)
|
|
See also: Receptor/signaling modulators
|
| Authority control |
- GND: 4142987-4
- NDL: 00560336
|